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High-dose-methotrexate therapy with eitrovorum factor (leucovorin) rescue has been widely used in the
treatment of many solid tumors and lymphomas. This therapy plays an important role in the
management of osteosarcoma1-7. The rationale behind using high doses of this drug is to achieve high
plasma levels (10 to 10-5 M)for prolonged periods8. This probably facilitates the passive entry of
methotrexate (MTX) into the tumor cells having defective transport systems9. It has also been
suggested that increased intracellular levels of free MTX can over come drug resistance caused by
increased levels of dihydrofolate reductase (DHFR) or presence of a DHFR having low affinity for
MTX10 Moreover, such high doses facilitate MTX polyglutamate formation within the tumor cells and
hence prolong its cytotoxie effects11. On these basis, such therapy has been advocated for base in
osteosarcoma1,2,6,7. The treatment has been shown to reduce regression of primary and metastatic
tumors12-16 and response rates seem to increase with more frequent and intense treatments14,17. More
recently, some workers have used 12 g/m2 of MTX which results in improved response rate and
survival18. Previously we have reported the treatment of two cases of metastatic osteosarcoma with
high doses (5 g/m2) of MTX19. Mega doses, however, have not been attempted in Pakistan due to its
prohibitive cost and toxicity. We recently treated a case of osteosarcoma with 12 g/m2 of MTX on four
different occasions. We monitored the MTX levels in the plasma as well as RBCs and evaluated the
toxicity and clinical outcome of this patient.
CASE REPORT
A twenty six year old male was admitted to the Aga Khan University Hospital in November, 1988 with
a history of right knee pain and later swelling of the lower end of femur. Radiologic examination
revealed an osteolytic lesion in the lower end of femur. A bone biopsy done in late October showed a
tumour composed of neoplastic cells with pleoniorphic, hyperchromatic nuclei, osteoid formation, foci
of calcification, scattered giant cells and areas of necrosis. He was diagnosed to have osteosarcoma. His
physical examination, except for above knee swelling, was normal. Metastatic work-up including
ultrasound liver and CT scan of chest was normal. Laboratory studies including CBC, electrolytes,
BUN and creatinine were normal. He was started on Rosen’s T-10 protocol20. Prior to chemotherapy,
patient received hydration and alkalinization of urine with NaHCO3 to keep the urine pH > 7.0.
Chemotherapy was carried out as shown in Figure 1.

MTX was administered as a continuous infusion over six hours. Blood sampling was done at regular
intervals to monitor MTX levels. Leucovorin rescue at 15 mg/m2 was started 24-hours after MTX
infusion every six hours until MTX level fell to <1.0 X 10-7 M.MTX concentration in plasma and
erythrocytes was determined by a very sensitive radioassay21. Erythrocytes were first washed with
saline and thea hemolysed in three volumes of deionized water and the proteins precipitated by placing
the hemolysate in a boiling water bath for 5 minutes. This exti-action procedure of the drug from
erythrocytes has been described elsewhere22. Profiles of MTX levels from plasma and erythrocytes
after a six hour infusion of MTX are shown in Figures 2 and 3.

Figure 2 shows that following all the four courses of MTX, the plasma levels of MTX during the first
12 hours following the completion of infusion remained within the range of 10-4 to 10-5 M. This is the
concentration that has been shown to facilitate passive diffusion of the drug into the tumor cells or

entry of the drug by a low affinity, high capacity carrier system9. Erythrocytes MTX profile during
these 4 courses is shown in Figure 3. In all the infusions, there was substantial entry of the drug (> 104
M) into erythrocytes probably by simple diffusion as well as by carrier system22. However, subsequent
to the first infusion, MTX levels in erythrocytes were found to be greater than 10-7 M at various time
intervals. These higher levels are partly contributed by newly formed red cells. At notime during the
course of treatment did the patient exhibit any symptoms of moderate or severe clinical toxicity. Mild
nausea and vomiting were the only complaints. Renal toxicity was effectively prevented by hydration
and urinary alkalinization23. Leucovorin rescue at 15mg/m2 every 6 hours was continued until MTX
levels fell below 1.0 x 10-7 M. This effectively prevented hematologic and mucosal toxicity. Moreover
at 48 hours post- infusion, MTX levels in plasma were well below 10-6M (Figure 2). Levels above 10-6
M at 48 hours are directly related to severe toxic effects19,23-25. Patient received three courses of MTX
at 12 Wm2 one week apart, followed one week later by chemotherapy with bleomycin,
cyclophosphamide and actinomycin-D. Three weeks later, he received fourth course of MTX (12
g/m2). At the end of the fourth course of MTX, he had achieved significant tumor regression. He
underwent amputation in February 1989. Since thenhe has been continued onT-lO protocol and till
today, remains disease free.
DISCUSSION
During the past several years, there has been a significant improvement in the disease-free survival of
patients with osteosarcoma. Although it has been mostly attributed to the use of adjuvant
chemotherapy, controversy remained as to the precise role played by chemotherapy. Some studies
clearly showed better outcome with the use of chemotherapy2,5-7, others maintained that the natural
history of the disease has changed to that of a better prognosis with surgery alone26. Regarding the
studies that failed to show the efficacy of the adjuvant chemotherapy, the poor response was attributed
to the use of chemotherapy, the poor response was attributed to the use of sub-optimal doses of MTX7.
More recently, two large multi-institutional studies have clearly established the role of chematherapy in
the management of osteosarcoma27,28. MTX at 12 g/m2 plays a central role in the drug combinations
used in the management of osteosarcoma6,18,20,27,28. These high doses have been suggested to increase
passive diffusion into the tumour cells and overcome drug resistance caused by amplification of DHFR
qene as well as the induction of a low-affinity DHFR9,10. This therapy, however, can be extremely
toxic. Major toxicity is severe mucositis, bone-marrow suppression and azotemia. Utilizing proper
precautionary measures, such as hydration and alkalinization of urine to decrease MTX precipitation in
the renal tubules and leucovorin rescue to prevent bone marrow suppression, this treatment can safely
be given. Indeed, in our patient no clinical toxicitywas observed. CBC, electrolytes, BUN and
creatinine were repeatedly measured and remained within normal limits. The MTX plasma levels
achieved were clearly in a range (10-4 to 10-5M) that is associated with enhanced passive diffusion of
drug into the tumor cells. Erythrocytes MTX levels also were indicative of substantial entry of drug
into the RBC's. After the first infusion, these levels were found to be greater than 10-7 M at different
time intervals. These higher levels are partly contributed by the MTX that got incorporated into the red
cell precursors in the bone marrow during the earlier infusions since RBC’s take 5-7 days to mature and
enter the circulation22. The efflux of MTX from the red cells as the plasma concentration decreases
may serve to deliver supplementary amount of the drug to the tissues. Since tumor tissue in
osteosarcoma has been shown to accumulate more drug than the surrounding normal tissue, this may
account for enhanced cytotoxic effect on the tumour cells while sparing the normal tissue5,29. The

clinical response in this patient is most encouraging. Twenty years ago, these patients had more than
80% chance of developing metastatic disease30. With the protocols similar to the one used here,
prognosis has improved to a disease-free survival of over 70% at 5 years31-33. This patient remains
disease free at 18 months of follow-up.
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